The FDA has approved Actonel with Calcium (risedronate sodium with calcium carbonate tablets, USP) for the treatment and prevention of osteoporosis in postmenopausal women. Although Actonel alone is currently available, the addition of calcium tablets makes this the first prescription osteoporosis medication to include calcium supplementation, a crucial part of osteoporosis pharmacotherapy.1
The formulation of Actonel with Calcium was prompted by the Surgeon General's 2004 Report on Bone Health and Osteoporosis, which found that the average adult consumes about 700 mg of elemental calcium dailysignificantly less than the recommended daily allowance of 1200 mg for women over age 50. Actonel with Calcium may provide the additional 500 mg of elemental calcium that may be missing from many adults' diets.2
In addition, the report summons all Americansboth the public and the health care communityto take the initiative in preventing and treating osteoporosis. Health care workers are encouraged to watch for red flags, such as multiple fractures in a patient under age 50 or health conditions that can lead to bone loss. Currently, 10 million Americans over age 50 have osteoporosis, and 34 million others are at risk for developing the condition.3
Actonel with Calcium consists of a once-weekly 35-mg risedronate tablet and six 1250-mg calcium carbonate tablets (500 mg of elemental calcium) to be taken on the remaining days of the week. It is packaged as a 28-day therapy and aims to increase patient compliance with calcium supplementation.1 Actonel with Calcium is marketed by the Alliance for Better Bone Health, a joint effort between Procter & Gamble Pharmaceuticals and Aventis Pharmaceuticals.2
Risedronate is a pyridinyl bisphosphonate that acts as an antiresorptive agent. By inhibiting osteoclast activity, risedronate reduces bone turnover, resulting in increased bone mass. Calcium is a major component in bone mineralization and also has an antiresorptive effect on bone.1
Contraindications,Warnings, and Precautions
Actonel with Calcium is contraindicated in patients with a known hypersensitivity to either component, an inability to remain upright for at least 30 minutes, or with hypo-or hypercalcemia. Patients should be aware that Actonel with Calcium might cause upper gastrointestinal disorders such as dysphagia, esophagitis, and ulcers. Osteonecrosis, especially in the jaw, has been reported with bisphosphonate use. Its use should be avoided in patients with a creatinine clearance of less than 30 mL/min.1 The most common side effects have been infection, back pain, and arthralgia.2
Pharmacists should instruct patients using Actonel with Calcium to follow these directions carefully:
Dr. Holmberg is a pharmacist with Phoenix Children's Hospital, Phoenix, Ariz.
For a list of references, send a stamped, self-addressed envelope to: References Department, Attn. A. Stahl, Pharmacy Times, 241 Forsgate Drive, Jamesburg, NJ 08831; or send an e-mail request to: email@example.com.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs